Association analysis between an independent variable (eg, a mtSNP or haplogroup) and a phenotype was performed using a linear mixed-effects model for a continuous phenotype and the generalized estimation equation model for a disease phenotype to properly account for residual correlation among related individuals. All of by guest on
H ypertension affects ≈1 billion people worldwide, including 75 million adults in the United States, and it is a major risk factor for myocardial infarction, heart failure, and stroke. 1 Although blood pressure (BP) has a substantial genetic component, with a heritability of long-term BP estimated at ≈55%, 2 the associated markers identified in genomewide association studies of BP and hypertension [3] [4] [5] [6] account for only a small fraction of interindividual variation, and the heritability of hypertension remains largely unexplained. 3, 7 To date, most of the reported genetic variants associated with BP in the population were identified in studies of the nuclear genome [3] [4] [5] [6] [8] [9] [10] [11] ; only limited insights have come from investigations of the mitochondrial genome. The 2 genomes that coexist in each human cell jointly specify the multimeric protein complexes of the major energy-generating oxidative phosphorylation (OXPHOS) pathway, 12 and the integrity of both genomes, their communication, 13 coordinated expression, and functional compatibilities 14 are required for energy homeostasis. Because the OXPHOS pathway mediates an individual's response to factors known to affect BP, such as diet and physical activity, inherited variation in the core OXPHOS subunits coded by the mitochondrial genome may contribute to interindividual BP differences and susceptibility to hypertension.
The human mitochondrial genome is a double-stranded circular molecule of ≈16.6 kb that encodes 37 genes, all contributing to a single pathway of energy production, including 13 protein subunits of the OXPHOS complexes and a set of 22 transfer RNAs and 2 ribosomal RNAs required for their translation. In contrast to the nuclear genome, the mitochondrial DNA (mtDNA) is present in hundreds to thousands of copies per cell and is inherited exclusively Abstract-Elevated blood pressure (BP) is a major risk factor for cardiovascular disease. Several studies have noted a consistent maternal effect on BP; consequently, mitochondrial DNA variation has become an additional target of investigation of the missing BP heritability. Analyses of common mitochondrial DNA polymorphisms, however, have not found evidence of association with hypertension. To explore associations of uncommon (frequency >5%) mitochon drial DNA variants with BP, we identified uncommon/rare variants through sequencing the entire mitochondrial genome in 32 unrelated individuals with extreme-high BP in the Framingham Heart Study and genotyped 40 mitochondrial single nucleotide polymorphisms in 7219 Framingham Heart Study participants. The nonsynonymous mitochondrial single nucleotide polymorphism 5913G>A (Asp4Asn) in the cytochrome c oxidase subunit 1 of respiratory complex IV demonstrated significant associations with BP and fasting blood glucose (FBG) levels. Individuals with the rare 5913A allele had, on average, 7-mm Hg higher systolic BP at baseline (P empirical =0.05) and 17-mg/dL higher mean FBG over 25 years of follow-up (P empirical =0.009). Significant associations with FBG levels were also detected for nonsynonymous mitochondrial single nucleotide polymorphism 3316G>A (Ala4Thr) in the NADH dehydrogenase subunit 1 of complex I. On average, individuals with rare allele 3316A had 17-and 25-mg/dL higher FBG at baseline (P empirical =0.01) and over 25 years of follow-up (P empirical =0.007). Our findings provide the first evidence of putative association of variants in the mitochondrial genome with systolic BP and FBG in the general population. Replication in independent samples, however, is needed to confirm these putative associations. (Hypertension.
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October 2012 from the mother. The 13 polypeptides are essential OXPHOS subunits that determine mitochondrial coupling efficiency, thus contributing to interindividual differences in energy use and, consequently, to the wide spectrum of metabolic phenotypes in the population. 15 In addition to energy production, mitochondria play a critical role in other cellular processes. 15 In the last decade, growing evidence has implicated mitochondrial dysfunction in a number of complex diseases, including autism 16 and metabolic syndrome. 17 Indirect evidence of mitochondrial genetic effects on BP and hypertension has come from correlation of mother-offspring BP levels [18] [19] [20] [21] [22] [23] and reports of maternal effects on hypertension status and quantitative systolic BP of offspring. [24] [25] [26] Although these findings are indicative of a mitochondrial pattern of inheritance, maternal effects may also reflect asymmetrical expression of parental alleles because of genetic imprinting 27 or indirect influence of maternal genotype on offspring phenotype. 28 Likewise, mtDNA mutations have been described in families with putative maternal inheritance of abnormal BP phenotypes, [29] [30] [31] [32] [33] but their causal role in hypertension has not been demonstrated, with a notable exception of the 4291 T>C mutation in the mitochondrial transfer RNA-isoleucine gene in a carefully characterized large kindred with a cluster of maternally transmitted metabolic defects. 34 To our knowledge, the association of specific mitochondrial mutations with interindividual BP variation in the general population has not been reported. In particular, a comprehensive analysis of common mtDNA variants compiled from publicly available data sets found no evidence of association with hypertension in 5 study samples. 35 We sought to test the hypothesis that uncommon mtDNA variants (frequency <5%) affect common complex phenotypes in the general population. To facilitate the discovery of infrequent alleles that influence BP, we sequenced the mitochondrial genomes of 32 unrelated individuals with extreme-high BP from the Framingham Heart Study (FHS), and a subset of variants identified in these individuals was genotyped in 7219 FHS participants and tested for associations with quantitative BP phenotypes. Because increased BP is a common feature of metabolic syndrome, a cluster of co-occurring CVD risk factors (obesity, hyperglycemia, dyslipidemia, and elevated BP), 36 we also explored potential associations of these variants with metabolic phenotypes. We report the results of our analyses of mitochondrial genome variants in relation to BP and several metabolic traits.
Methods
Please refer to the online-only Data Supplement for methods used to identify maternal lines and mitochondrial lineages (haplogroups); to conduct mtDNA sequencing and sequence analysis, genotyping, and the quality control of the genotype data; and for expanded description of association and permutation analyses of mitochondrial single nucleotide polymorphisms (mtSNPs) and haplogroups.
Study Participants
In 1971, children and spouses of children of the original FHS cohort participants were recruited into the Framingham offspring cohort, which consists of 5124 men and women. 37 The FHS offspring participants have been examined every 4 to 8 years, 37, 38 and, unless specified otherwise, common clinical phenotypes from all examinations were available for this investigation. From 2002 to 2005, a third-generation cohort of 4095 individuals was recruited to the FHS. 39 Because of the recent recruitment of the FHS third-generation cohort, clinical data from only a single examination were available for this study. All of the participants gave written informed consent for genetic research. All of the protocols in this study were approved by the institutional review board of Boston University Medical Center.
BP Phenotypes
At each clinic visit, BP was measured twice by a physician, and the 2 BP measurements were averaged to derive the systolic (SBP) and diastolic BP (DBP) for that examination. If only 1 BP measurement was obtained, its value was used for that examination. For participants receiving antihypertensive medication, adjusted SBP and DBP were calculated by adding 10 mm Hg and 5 mm Hg to the measured SBP and DBP values, respectively. 2 Other exclusion criteria were described previously. 2, 40 To evaluate genetic associations using both single occasion measures and longitudinal phenotypes, we constructed several phenotypes for SBP and DBP. We defined the "baseline" BP traits as the BP values at examination 1 of the offspring (1971) (1972) (1973) (1974) (1975) and the third-generation (2002-2005) cohorts. "Contemporary" BP traits (reflecting ascertainment contemporaneously with DNA collection) were measured at examination 7 (1998-2001) of the offspring participants and at examination 1 of the third-generation participants. "Long-term averaged" BP was calculated separately for SBP and DBP using mean values across examinations 1 to 7 of the offspring participants with data from ≥3 clinic examinations. In addition to continuous BP traits, we analyzed hypertension as a categorical phenotype, defined as SBP of ≥140 mm Hg or DBP of ≥90 mm Hg or current antihypertensive drug treatment at the contemporary BP examination.
Metabolic Phenotypes
Body mass index (BMI) was used as an index of obesity. To calculate BMI, weights (in kilograms) at each examination cycle of the offspring cohort and at the initial examination of the thirdgeneration cohort were used in conjunction with height (in meters) at the initial examination. In parallel with BP phenotypes, 4 adiposity phenotypes were used in this study. The baseline, contemporary, and long-term BMI phenotypes were defined similarly to those for BP phenotypes. In addition, a participant was defined as obese if his/her BMI was ≥30 kg/m 2 for the contemporary BMI measurement.
Four FBG-based traits were used in association analyses. Because fasting status was not uniformly ascertained at the first 2 examinations of the offspring cohort, the baseline phenotype used FBG at examination 3 of offspring participants and examination 1 of the third-generation cohort. The contemporary phenotype consisted of FBG at examination 7 of the offspring and examination 1 of the third-generation cohort. In continuous trait analyses of FBG, we excluded individuals receiving drug treatment for diabetes mellitus who had an FBG <126 mg/dL. Diabetes mellitus was defined as an FBG of ≥126 mg/dL or currently receiving insulin or hypoglycemic drug treatment for diabetes mellitus at the contemporary examination. Long-term FBG was calculated over examinations 3 to 7 of the offspring cohort for all of the participants who had ≥2 FBG values.
Additional continuous phenotypes included serum K + and Mg 2+ levels measured at examination 2 of the offspring cohort 41 and fasting insulin levels measured at examination cycles 7 and 1 of the offspring and third-generation cohorts, respectively. 42 Detailed information about these traits is described in the online-only Data Supplement. the association analyses were conducted using R software. Permutation testing was carried out to account for multiple testing, correlations among traits, and to minimize potential false findings from mtSNPs with low minor allele frequencies.
Results
Expanded results are provided in the online-only Data Supplement. Table 1 summarizes the characteristics of the study participants at the initial examinations of the 2 study cohorts. At their initial clinic visits, the third-generation cohort individuals were, on average, ≈5 years older than the offspring cohort participants (40.2 versus 34.9 years), had higher BMI (26.9 versus 24.9 kg/ m 2 ), and had a higher prevalence of obesity. Although the thirdgeneration and offspring cohorts had approximately equal proportions of hypertensive individuals (≈16%), a higher proportion was treated for hypertension in the third-generation cohort (8.2% versus 2.2%). Table S1 (in the online-only Data Supplement) summarizes the contemporary BP and metabolic phenotypes of the 2 cohorts. Except for DBP, which was similar in both cohorts, all of the other trait values were higher in the offspring than in the third-generation cohort because of the age difference between the 2 cohorts at the contemporary examination. By design, only the offspring cohort participants contributed to the long-term measurements (Table S2 ). Moderate-to-high correlation was observed across traits within several phenotype categories (eg, BP/hypertension, BMI/obesity, and FBG/diabetes mellitus). The correlation (measured by the Pearson correlation coefficient) ranged from 0.4 to 0.8 for BP phenotypes, 0.6 to 0.9 for BMI phenotypes, and 0.5 to 0.8 for FBG phenotypes ( Figure S1 , available in the online-only Data Supplement). Table 2 summarizes the information for 40 mtSNPs used in association analysis. These mtSNPs were matched with the positions in reference of the Revised Cambridge Reference Sequence (GenBank No. NC_012920). 43 Four of the 40 mtSNPs genotyped in 7219 FHS individuals were excluded from association analyses because of very low minor allele frequencies (MAF) ( Table 2 ). The association results that remained significant after adjustment for multiple testing (P empirical ≤0.05) are presented in Table 3 . Additional association results with observed P values ≤0.05 are provided in Tables S3-S7 .
Characteristics of the Study Participants

Association Analyses
The association between mtSNP 5913G>A and baseline SBP remained significant after correction for multiple testing (Table 3 ). Individuals harboring the rare allele 5913A (MAF=0.6%) had, on average, 7-mm Hg higher SBP at baseline than those with the common G allele. Additional permutation analyses across continuous phenotypes at 3 time periods (baseline, contemporary, and long-term averaged) demonstrated significant associations of 5913A (P empirical sum =0.005) across the 3 SBP phenotypes (Table S8) .
For FBG traits, several associations remained significant after permutation analyses. The variant 3316G>A (MAF A = 0.4%) showed associations with baseline (P empirical =0.01) and long-term average (P empirical =0.007) FBG. Individuals with the rare allele 3316A had, on average, 17-and 25-mg/ dL higher FBG at baseline and over 25 years of follow-up, respectively. In addition, the variant 5913G>A demonstrated association with contemporary (P empirical =0.03) and long-term average (P empirical =0.009) FBG. Individuals with the rare allele 5913A had 13-and 17-mg/dL higher FBG, respectively, at the contemporary examination and during long-term followup than those with the common allele. This variant also demonstrated a significant summary P value (P empirical sum =0.007) across the 3 FBG traits (Table S8) . After correction for multiple testing, no association remained significant for BMI-related phenotypes (Table  S5) , insulin levels (Table S6 ), or K + or Mg 2+ levels (data not shown). No association with phenotypes remained significant between common European haplogroups (Supplementary Methods, available in the online-only Data Supplement) after permutation analysis (Table S7 ).
Discussion
In recent years, the conventional view of mitochondria as static power plants that burn the dietary calories for energy and heat production and house metabolic pathways has been revised and expanded. It is now appreciated that mitochondria form dynamic cellular networks that integrate external and internal signals to regulate numerous cell processes in addition to energy production and thermogenesis, including calcium homeostasis, cellular redox state, reactive oxygen species, and apoptosis. 15 Epidemiological studies have demonstrated that mitochondrial disorders are common, 44, 45 and the imbalance between energy intake and expenditure is now recognized as an important factor in diverse pathologies, including common multifactorial disorders. 16, 17 The primary goal of this study was to identify mitochondrial genetic determinants of BP. We also explored the effect of mtDNA variants on several metabolic traits. To our knowledge, this is the largest family based study of mitochondrial genomic variation in relation to BP and metabolic phenotypes conducted to date.
Results of our investigation provide support for the hypothesis that rare/uncommon alleles in the mitochondrial genome modulate complex quantitative phenotypes. In particular, we identified an association between mitochondrial variant 5913G>A (rs201617272) in cytochrome c oxidase subunit 1 (MT-CO1) and BP levels. Individuals with a rare 5913A allele had, on average, 7-mm Hg higher baseline SBP than those with a common 5913G allele. Remarkably, this variant has also demonstrated association with FBG levels; individuals with 5913A had, on average, 17-mg/dL higher mean FBG over 25 years of follow-up. Associations with FBG levels were also detected for SNP 3316G>A (rs2853516) in NADH dehydrogenase subunit 1 (MT-ND1). Individuals with the rare allele (Continued) *The position of a mitochondrial variant within the Revised Cambridge Reference Sequence (GenBank NC_012920) 43 and its common>minor alleles. For a nonsynonymous mtSNP, the changed amino acid and its position within the protein are shown in parentheses. All of the nucleotide changes are indicated as L-strand substitutions.
†MAF and minor allele frequency were calculated using the entire sample. ‡MtSNPs were excluded from statistical analysis because of low call rate (<95%, mt456) or having <10 variants (mt8255, mt8411, and mt15889) in the entire sample.
§The mtSNPs that define the 9 major European mtDNA haplogroups. 3316A demonstrated higher FBG levels than those carrying the common 3316G allele, especially in long-term analyses, suggesting its lifelong effects. The OXPHOS pathway is at the core of mitochondrial function and dysfunction. Both 3316G>A in MT-ND1 and 5913G>A in MT-CO1 are rare nonsynonymous mutations and may affect the functional properties of the respective OXPHOS complexes of ATP synthesis. Although overtly pathogenic mutations result in severe and frequently fatal neuromuscular and metabolic diseases, 46 milder mutations may have subtle phenotypic consequences. Mitochondrial SNP 3316A replaces the nonpolar alanine at position 4 of MT-ND1 with a polar threonine, and SNP 5913A substitutes the negatively charged aspartic acid at position 4 of MT-CO1 with a neutral asparagine. Neither change involves the highly conserved site or the known functional domain, and the predicted pathogenicity scores for 3316G>A and 5913G>A are 0.463 and 0.197, respectively. 47, 48 Therefore, both missense mutations are likely to have subtle effects on protein function. These score values, however, are based on the programs designed primarily to quantify the severity of mutations in single-gene diseases 49 and may not necessarily apply to lateonset multifactorial disorders. 49 Interpretation of predictive scores is further obscured because of potential interactions of mitochondrial subunits with each other and with nuclear proteins. Moreover, the same mtDNA variant may be either deleterious or beneficial depending on the haplogroup and the environmental context. 50 These properties are not integrated in the prediction scores, necessitating "bench" experimentation to ascertain the effects of a mutation on OXPHOS function.
To our knowledge, no disease association has been reported previously for SNP 5913G>A. This variant defines rare subclade K1b of haplogroup K, 51 and in our sample, 41 individuals from 16 maternal lines who carried this variant belonged, in fact, to haplogroup K. However, a search of public databases revealed that 5913A also resides on other haplogroup backgrounds [47] [48] [49] [50] [51] [52] (in Pereira et al 47 and in Rubino et al 52 ). It would be interesting to see whether the effect of 5913A on OXPHOS function is modulated by haplogroup background. The 3316A variant occurred in multiple haplogroups in our study sample. Sixteen of the 24 individuals who had the rare allele belonged to 4 haplogroups (unambiguous assignment of the remaining 8 individuals to 1 of 9 common European haplogroups was not possible). Previously, 3316G>A was reported in isolated cases of cardiomyopathy 53 and in diabetic patients with left ventricular hypertrophy. 54 Our findings suggest that rare variants in the mitochondrial genome may play an important role in the development of hypertension and diabetes mellitus. Replication of our results in independent study samples is warranted, although very large sample sizes are required to identify associations with such low-frequency (0.4% to 0.6%) variants. Inadequate sample sizes and the focus on common mtDNA polymorphisms and major haplogroups may explain the failure of earlier population-based association studies to identify an association of mtDNA variants with BP and metabolic traits. 35, 55, 56 Advances in sequencing may facilitate the identification of rare mitochondrial variants in additional large study cohorts and allow replication of our findings in the near future.
Perspectives
Results of our investigation have yielded further clues into the genetic causes of common complex disorders. Our findings also suggest that the mitochondrial genome may harbor additional rate variants that contribute to the risk of hypertension and metabolic disorders in the population. Drastic decreases in the cost of sequencing now make it possible to sequence the entire mitochondrial genome in hundreds of individuals at a relatively low cost. Such efforts are likely to identify additional rare causal mtDNA variants.
The associations that we observed involve rare nonsynonymous mutations. The actual effects of the 5913A and 3316A variants on OXPHOS remains to be determined by functional studies. The analysis of intergenic interactions within the mitochondrial genome and between the mitochondrial and nuclear loci is another important venue of inquiry into mechanisms involved in the development of hypertension and metabolic syndrome. 
Sources of Funding
Disclosures
None. 
What Is New?
• We identified uncommon mtDNA variants through sequencing of the entire mitochondrial genome from individuals with extreme BP values. Our association analyses demonstrated evidence of association between two rare mtDNA variants with SBP and FBG in the general population. These variants code for amino acid changes in two proteins that serve vital roles in oxidative phosphorylation.
What Is Relevant?
• If confirmed in other populations, our findings would indicate that rare mitochondrial variants may have clinically relevant effects on interindividual variation in blood pressure.
Summary
We present the first evidence of associations of mtDNA variants with SBP and FBG in the general population. In contrast to earlier population-based association studies of common mtDNA polymorphisms (frequency 5%) and major mitochondrial haplogroups with BP and metabolic traits, the focus of our investigation was on uncommon/rare variants (frequency 1%) identified through sequencing the entire mitochondrial genome in 32 unrelated individuals with extreme-high BP.
If confirmed in other populations, our findings may have clinical implications for individuals harboring causal mtDNA variants. Our results also suggest that extensive resequencing efforts directed at the mitochondrial genome will likely reveal additional variants modulating BP and metabolic phenotypes 
Novelty and Significance
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K + , Mg 2+ and fasting insulin phenotypes
Additional continuous phenotypes included serum K + and Mg 2+ levels measured at examination 2 in the offspring cohort, and fasting insulin levels measured at examination cycle 7 of the offspring cohort and examination cycle 1 of the third generation cohort. Serum K + and Mg 2+ levels were measured from fasting blood samples. Potassium was measured using standard ion electrode devices while Mg 2+ was measured by MetPath laboratories with the method described previously 1 . Insulin was measured using radioimmunoassay in the offspring cohort and enzymelinked immunosorbent assay in the third generation cohort 2 . Diabetic individuals were excluded from insulin analysis. To reconcile the data in the two cohorts due to different insulin assays, cohort-specific age-, sex-, and BMI-adjusted normalized residuals were obtained for logtransformed insulin levels. The pooled residuals were used in subsequent association analyses.
Defining Maternal Lineages in FHS
In all Framingham pedigrees, the founders and the married-in individuals were assigned distinct numbers that denote their maternal lineages. The female founders and the married-in females share a common number with their respective offspring and the descendants of female offspring. The example of a hypothetical pedigree is shown in the Supplementary Figure 2 .
In the absence of inherited heteroplasmy (defined as the occurrence of more than one mtDNA genotype in an individual) or a de novo mutation, all individuals in the same maternal lineage possess identical mtDNA sequences. As a result, the missing genotypes can be inferred by comparing the genotypes across multiple individuals within the same maternal lineage. Moreover, the haplotype for each individual can be constructed by concatenating the alleles across all mtSNPs. By comparing the haplotypes across different maternal lineages, we can infer cryptic relatedness between maternal lineages to trace back a common maternal ancestor. In addition, permuting haplotypes across maternal lineages preserves correlation among mtSNPs in permutation testing (as described below).
Mitochondrial DNA Sequencing
Genomic DNA from the lymphoblastoid cell lines was used for mtDNA sequencing and mtSNP genotyping. To identify participants with extreme BP, age-, sex-, and BMI-adjusted residuals were obtained separately for SBP and DBP measurements from 1,802 unrelated individuals from the FHS offspring cohort. The residuals of these two BP measures were summed up and ranked, and thirty-two individuals from the top ranked residuals were selected for the mitochondrial genome sequence determination.
The entire mitochondrial genomes from 32 FHS individuals were amplified by polymerase chain reaction (PCR) as described previously 3 , using the 58 sets of reference oligonucleotide primers recommended by the National Institute of Standards and Technology (Gaithersburg, Maryland) 4 and custom-made by Integrated DNA Technologies (Coralville, IA), and the PCR products were sequenced by Agencourt Bioscience (Beverly, MA). All electropherograms were checked manually to resolve sequencing artifacts and ambiguous base calls. In some cases, additional sequencing was performed from the opposite DNA strand. For each individual, the data from 58 sequencing reactions were assembled into a single mtDNA contig using the VectorNTI software (Informax, Inc). Mitochondrial DNA variants were identified through sequence alignments with the mtDNA reference sequence (the revised Cambridge Reference Sequence, rCRS, accession number: NC_012920) 5 , tabulated, and individually followed up with on-line sequence analysis tools and mitochondrial databases (listed in References).
mtSNP Genotyping
The following categories of mitochondrial variants were selected for follow-up genotyping: 1) the ten mtSNPs that define nine major European mitochondrial lineages 6, 7 (referred to as haplogroup-defining mtSNPs) ; 2) infrequent nonsynonymous variants; 3) tRNA variants; and 4) noncoding variants within mtDNA control elements.
The selected mtSNPs were submitted to Illumina to obtain a design feasibility rank score for each variant to be included on an iSelect chip (Illumina, Inc. San Diego, CA). The DNA samples were submitted to the Illumina FastTrack Service for genotyping according to the manufacturer's instruction. All mtDNA loci in the iSelect product were reviewed for clustering accuracy. Unlike the calling algorithm for a SNP in the nuclear genome where three clusters are expected, the mtSNP calling algorithm uses two clusters because heteroplasmy in blood samples is rare.
The ten haplogroup-defining mtSNPs (mt1719 G>A, mt4580 G>A, mt7028T>C, mt8521 G>A, mt9055G>A, 10398A>G, mt12308A>G, mt13368G>A, mt13708G>A, and mt16391G>A) were initially genotyped in 1,802 unrelated individuals from the FHS offspring cohort using the 5′ nuclease allelic discrimination Taqman assay (Applied Biosystems, Foster City, CA) in a 384well format on the ABI Prism 7900HT Sequence Detection System (SDS), as previously described 7 . The primer and probe sequences for each SNP genotyping assay were provided by Dr. van der Walt (personal communication) and manufactured by Applied Biosystems. These mtSNPs were also included on the iSelect chip (Illumina, Inc. San Diego, CA) and genotyped in 7,219 FHS individuals by the Illumina FastTrack Service.
Quality control
Quality control of genetic data was carried out in two steps. The first step was to compare genotypes of each variant among all individuals within the same maternal lineage. If an individual had a different genotype from all others in the same maternal lineage, his/her genotype was set to be missing for that variant only. Heteroplasmic genotypes were also set to missing due to the rarity of such occurrences. The second cleaning step was to compare genotypes for the haplogroup-specific mtSNPs that were genotyped by both the high-throughput iSelect chip (Illumina, Inc.) and the 5' nuclease allelic discrimination Taqman assay (Applied Biosystems, Inc.) as described above. Discordant genotypes were set to missing for both datasets.
Association analysis
Association analysis between an independent variable (e.g., mtSNP or haplogroup) and a phenotype was performed using a linear mixed effects (LME) model for a continuous phenotype and the generalized estimation equation (GEE) model for a disease phenotype to properly account for residual correlation among the related individuals. Association analysis was conducted using the R software.
Association analyses for single mtSNPs: In a maternal lineage, the genotypes are identical for all subjects, whereas their phenotypes may vary. In LME, a genotype variant was modeled as a fixed effect and the polygenic effect (from the nuclear and mitochondrial genomes) was modeled as a random effect to account for the residual correlation within families. In GEE, each family was treated as a cluster, with an independence working correlation matrix used as the robust variance estimator. Covariates were sex, age, BMI, and "generation" (0/1 variable to indicate if a subject was from the offspring or the third generation cohort). Because genomewide SNP data (Affymetrix 500K and MIPS 50K combined) and the top ten eigenvectors from principal component analysis (PCA) were available for all subjects in this study, we were able to account for intra-European population stratification among participants in the regression model by incorporating the top eigenvectors that were related to phenotypes as additional covariates in the LME or GEE model 8, 9 . mtSNPs were coded as 0/1 since all genotypes were homoplasmic.
Association analyses for haplogroups: In general, association analysis for haplogroups was similar to that for single mtSNPs. The LME and GEE models were employed for continuous and binary traits, respectively. The same set of covariates was adjusted for in the statistical models. However, different coding schemes were needed to code the nine European haplogroups for association analysis. We considered two methods to code haplogroups. In the first method, the largest haplogroup H was used as the reference. In the second method, one haplogroup was compared to all other haplogroups combined.
Permutation Test
Permutation testing was carried out to account for multiple testing, correlations among traits, and to minimize potential false findings from mtSNPs with low minor allele frequencies. As described above, in a state of homoplasmy, all individuals in the same maternal lineage possess the same genotypes at all mtDNA loci. Therefore, each maternal lineage possessed only one haplotype, allowing the permutation test to be performed in the following four steps. A) The haplotypes were shuffled across all independent lineages. The permuted genotypes can then be obtained for each subject based on the permuted haplotypes. B) In each iteration, association tests were performed for all phenotypes simultaneously. C) The shuffle of the haplotypes was performed 10,000 times and association tests were performed repeatedly between permuted mtSNPs and non-permuted phenotypes, resulting in null distributions of association p-values. D) An empirical p-value was calculated as the fraction of permutation p-values ≤ an observed pvalue in equation 1 (below). Two empirical p-values for a mtSNP were calculated using Equation 1. P empirical for each trait was calculated by comparing the observed p-value with the pooled minimum permutation p-values across all mtSNPs in each replicate to correct for multiple testing across the mtSNPs. Continuous phenotypes were formed at three stages for BP, FBG, and BMI categories and a certain amount of correlation among the traits was expected within each category, which may result in significant association with the same variant for more than one trait within a category. To account for correlation among the continuous traits at three stages, a summary measure of association, P empirical_sum , was computed in the following three steps: 1) p_0 was obtained by summing up of the observed p-values from three traits within each trait category; 2) the minimum of the sum of three-trait permutation p-values across all mtSNPs was obtained in each of 10,000 permutations and the resulting value for the r th permutation was designated as p_r; and 3) P empirical_sum for a mtSNP was imputed as the proportion of p_r ≤ p_0. Both P empirical and P empirical_sum account for multiple testing across mtSNPs, but the latter emphasizes the consistency of the association of a mtSNP across multiple correlated traits at different stages.
Supplementary Results
Sequence analysis
Comparison with the revised Cambridge Reference Sequence 5 has identified a total of 305 variants among the 32 FHS individuals with extreme-high BP, including 83 non-coding and 222 coding-sequence variants. Of the non-coding variants, 79 were within the D-loop region, including 74 SNPs, one 1bp deletion, and four sites involving the variable length polycytosine tract heteroplasmy; and four variants (2 SNPs and 2 small deletions) were within the intergenic spaces. The coding-sequence variants included 12 SNPs and one C-tract heteroplamy in the 12S rRNA; 18 SNPs in the 16S rRNA; 16 SNPs in tRNA genes; and 175 SNPs in the protein-coding genes, of which 129 SNPs were synonymous substitutions and 46 were nonsynonymous SNPs.
European mtDNA haplogroups H, I, J, K, T, U, V, W and X were classified according to the published references 6, 7 and the Mitomap database 10 . All nine major European haplogroups (H, I, J, K, T, U, V, W and X) were identified in the 32 sequenced mtDNAs as follows: haplogroup H=12 individuals; U=7; I=4; J=2; T=1; K=1; V=1; X=1; W=1; and 1=undetermined.
Classification of maternal lineages and construction of haplotypes
A total of 7,219 participants belonged to 2,589 independent maternal lineages (size ranges 1 to 26). Of these 2,589 lineages, 1,115 were singletons. The 1,474 remaining lineages contained two or more individuals and we refer to these as "multi-member lineages." We further classified these multi-member lineages into three categories, small lineages -containing two to five individuals (n = 1,186), medium sized -containing six to ten individuals (n = 237), and largecontaining 11 to 26 individuals (n = 51).
We constructed a haplotype for each individual by concatenating alleles across all mtSNPs to facilitate data cleaning and permutation testing (Supplementary section). Haplotype frequency was evaluated in each maternal lineage, confirming that all subjects in the same lineage possess an identical haplotype. measured using radioimmunoassay in the offspring cohort and enzyme-linked immunosorbent assay in the third generation cohort 2 . Diabetic individuals (FBG ≥ 126 mg/dL or currently receiving insulin or hypoglycemic drug treatment for diabetes) were excluded from insulin analysis. To reconcile the data in two cohorts due to different assay methods, cohortspecific age-, age 2 -, sex-, and BMI-adjusted residuals were obtained for log-transformed insulin levels. The pooled residuals were used in subsequent association analysis. G 0.045 0.74 Note: * beta estimate and standard error (SE) estimated from linear mixed effects (LME) and generalized equation models for continuous and binary traits, respectively; † p-value obtained with observed data; ‡ p-value obtained from comparing the observed p-value with pooled smallest permutation p-values of all mtSNPs for a trait after 10,000 permutation of the haplotypes. BP=blood pressure. 6013 0.10(0.04) C 0.012 0.69 * Beta estimate and standard error (SE) were estimated from linear mixed effects (LME) and generalized equation models for continuous and binary traits, respectively. † P-value was obtained with observed data. ‡ P-value was obtained from comparing the observed p-value with pooled smallest permutation pvalues of all mtSNPs for a trait after 10,000 permutation of the haplotypes. BP=blood pressur. Body mass index 3505A>G 0.87 5460G>A 0.54 8251G>A 1 * p-value was imputed by comparing the sum of the observed p-values of the three continuous traits within each trait category to the pool of the minimum of the sum of three permutation pvalues across all mtSNPs in each of 10,000 permutations.
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